Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection (Q38990715)

8 September 2017

Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection (English)

1 reference

8 September 2017

1 reference

1 reference

1 reference

11

Christophe Hézode

0 references

Jean-Michel Pawlotsky

1

object named as

Jean-Michel Pawlotsky

0 references

Robert Flisiak

2

object named as

Robert Flisiak

1 reference

8 September 2017

10

Heiner Wedemeyer

1 reference

8 September 2017

5

Teerha Piratvisuth

1 reference

8 September 2017

Jean-Michel Pawlotsky

1

1 reference

8 September 2017

Shiv K Sarin

3

1 reference

8 September 2017

Jens Rasenack

4

1 reference

8 September 2017

Wan-Long Chuang

6

1 reference

8 September 2017

Cheng-Yuan Peng

7

1 reference

8 September 2017

Graham R Foster

8

1 reference

8 September 2017

Samir Shah

9

1 reference

8 September 2017

Christophe Hézode

11

1 reference

8 September 2017

Wei Zhang

12

1 reference

8 September 2017

Kelly A Wong

13

1 reference

8 September 2017

Bin Li

14

1 reference

8 September 2017

Claudio Avila

15

1 reference

8 September 2017

Nikolai V Naoumov

16

1 reference

8 September 2017

VITAL-1 study team

17

1 reference

8 September 2017

language of work or name

English

0 references

publication date

27 June 2015

1 reference

8 September 2017

1 reference

8 September 2017

62

1 reference

8 September 2017

1013-1023

1 reference

8 September 2017

4

1 reference

Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence

8 September 2017

1 reference

A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel

21 January 2018

1 reference

The global health burden of hepatitis C virus infection

21 January 2018

1 reference

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

21 January 2018

1 reference

Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

21 January 2018

1 reference

Is genotype 3 of the hepatitis C virus the new villain?

21 January 2018

1 reference

Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3.

21 January 2018

1 reference

Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

21 January 2018

1 reference

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

21 January 2018

1 reference

Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.

21 January 2018

1 reference

Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C.

21 January 2018

1 reference

Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C

21 January 2018

1 reference

Role of hepatitis C virus genotype 3 in liver fibrosis progression--a systematic review and meta-analysis

21 January 2018

1 reference

High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials

21 January 2018

1 reference

Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: final results from the STEPS trial

21 January 2018

1 reference

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

21 January 2018

1 reference

Sofosbuvir for previously untreated chronic hepatitis C infection

21 January 2018

1 reference

The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection

21 January 2018

1 reference

Completion of the entire hepatitis C virus life cycle in genetically humanized mice

21 January 2018

1 reference

Profile of alisporivir and its potential in the treatment of hepatitis C.

21 January 2018

1 reference

Structural basis for the non-immunosuppressive character of the cyclosporin A analogue Debio 025.

21 January 2018

1 reference

DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A

21 January 2018

1 reference

The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients.

21 January 2018

1 reference

Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir

21 January 2018

1 reference

The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance

21 January 2018

1 reference

Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors

21 January 2018

1 reference

Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients

21 January 2018

1 reference

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection

21 January 2018

1 reference

Sofosbuvir and ribavirin in HCV genotypes 2 and 3.

21 January 2018

1 reference

All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study

21 January 2018

1 reference

Cyclophilin inhibition as potential therapy for liver diseases

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/HEP.27960

1 reference

8 September 2017

1 reference